Director Edward T. Anderson resigns from Lyra board; Snyderman appointed to Audit Committee

Lyra Therapeutics, Inc.

Edward T. Anderson resigned from Lyra's Board, Audit Committee, and Compensation Committee effective April 15, 2024.
Nancy L. Snyderman was appointed to the Audit Committee on April 15, 2024, filling the vacancy.
Anderson had been a Board member since 2019 and an investor since 2006; no reason for departure given.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Edward T. Anderson

Director

LYRA · Lyra Therapeutics, Inc.

Effective: 2024-04-15
Filed: April 19, 2024, 7:59 PM ET

On April 15, 2024, Edward T. Anderson resigned from the Board of Directors (the “ Board ”) of Lyra Therapeutics, Inc. (the “ Company ”) as well as the Audit Committee and Compensation Committee of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Edward T. Anderson resigned as Director at Lyra Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On April 15, 2024, Edward T. Anderson resigned from the Board of Directors (the “ Board ”) of Lyra Therapeutics, Inc. (the “ Company ”) as well as the Audit Committee and Compensation Committee of the Board.

View on SEC.gov

Lyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-102914

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.